Relina (TP7193SL) in Vascular Dementia

TP7193SL is designed as delivery-optimized, disease-modifying  candidate VaD drug to prevent or rescue the neurovascular disarray. 


  • Vascular dementia (VaD) is a unmet medical need while also aggravates Alzheimer’s and other neurodegeneration-driven dementia. 

  • VaD is the worst-served medical need in neurological space since no specific therapeutic options are available for vascular cognitive impairment, alone or in mixed AD dementia.

  • TP7193SL is designed as delivery-optimized, disease-modifying candidate VaD drug to prevent or rescue neurovascular derangement in pre-dementia or dementia patients. 

    • Sublingual TP7193SL (Relina™) is a vascular-neurotrophic therapeutic via autocrine-driven regeneration;

    • A mode of action is autophagy, self-cleaning rejuvenation prompted within endothelial and neural cells;

    • TCPTP agonism complements the regenerative processes by elicited vascular and neuronal reinforcement;

    • Noteworthy, in preliminary in vitro study TP7193 comes out to be inhibitory on SARS- CoV-2 viral infections.  

  • TP7193SL supports neurovascular functionality and trophicity by anti-senescence action, assists vascular and synaptic connectivity upon brain insults, and induces hypotension.

  • Fast-track clinical entry may bypass the inertial lag-time of the classic Rx drugs.

  • Co-development or early licensing is sought.


While half of dementia patients have forms of neurovascular impairment, VascularDementia (VaD) is considered (Takeda Corp.) the worst-served medical need in neurological space, and beyond.

No specific therapeutic options are currently available to improve the condition of patients with VaD and cognitive impairment and mixed AD dementia with a vascular comorbidity.Palliative regimens consists in direct anticoagulants or warfarin, anticholinergics, nitrodilators; or experimental use of phosphodiesteraseinhibitors and alpha-blockers, that may afford some cognitive relieves.

VaD may be a stand-alone disease, or may aggravates 40% of Alzheimer’s disease (AD) and other neuro-degenerations (OND), including Lewy’s body and frontotemporaldementia. 

TP7193SL targets the molecular pathways that sustains a trophic vascularity while also assists the synapses regrowth, fluidity and neuronal connections. 

TP7193SL have been designed in at least two versions: 

Relina sd: solid form, to prevent risky elderly or treat early clinical onset of VCI

Relina lq: liquid form, suited for the assisted VaD treatment or as AD co-therapy


Several preclinical studies confirmed a positive neurovascular activity; while separate clinical trials are in progress on Cardiovascular and Neurological risks, respectively, by food-approved oral dosed forms.

Tixupharma’s IP core consists in targeted delivery by TP7193SL, since the sublingual route can uniquely reach a therapeutically effective local dose.